

NEUROLOGIE BERLIN-MITTE

Friedrichstraße 185
10117 Berlin (Mitte)

Telefon 030·44 88 60 2
Telefax 030·42 80 92 72

praxis@neurologie-berlin-mitte.de
www.neurologie-berlin-mitte.de

Neurologie Berlin-Mitte · Friedrichstr. 185 · 10117 Berlin

Narendra
Jana

Berlin, 19.03.2019

Herrn **Narendra Nirmal Jana**, geb. am 27.10.1984
wh.: Markgrafenstr.68, 10969 Berlin

Background:

Narendra Jana is a 34-year-old university graduate, who is an engineer by profession and presented with relapse remitting multiple sclerosis historically but secondary progressive MS now due to length of clinical course (approximately 12 years).

His records indicate normal developmental milestones and above average aptitude prior to clinical presentation of MS.

He is a non drinker and non recreational drug user and never has been historically.

Under my Care (since March 2018):

Narendra Jana, patient since March, 2018 presented as a follow up from an ER appointment in Bundeswehrkrankenhaus, Berlin on the 17th of March 2018 with a clinical history of MS starting from 2008.

He presented in ER with a "fixation disturbance and nystagmus hypoesthesia entire left body halftone, decreased reflex status left" and "finger-pointing" difficulties.

I was recommended "for further therapy. In summary, a sufficient long-term therapy and regular connection to a Neurologist".

The treatment started in ER (IV methylprednisolone) was completed with three more days of IV methylprednisolone given 1 gram each day outpatient in my clinic.

Rebif 20 mcg was prescribed thereafter taken every other day trialed for a period of 5 months from March 2018 to July 2018.

Due to limited efficacy the patient was switched to Tecfidera 240 mg twice a day from July 2018 to January 14th 2019.

A VEP was done in August 10th 2018 showing "left optic neuropathy".

A neuropsychological report dated August 11th 2018, indicated reduced processing speed with his executive functioning and decision making mostly preserved. Tests for visual attention and task switching is below cut off. Tests with respect to global functioning, memory functioning, attention span, and language are average.

Three days of IV methylprednisolone were administered in July 2018 by Dr. Luis Amaya in Mexico City again.

Narendra
Jana

With the given information the patient researched Rituximab by consulting several hospitals in Europe and presented his clinical history to a clinician in India, Dr. Pushendra Renjen, and the neurology team in Apollo Hospital, New Delhi. Rituximab was administered following a blood test and JV Virus test at a dose of 1 gram separated by two weeks (two times) as the starting dose

The neurologist also did a VEP test to show the progressive demyelinating optic neuropathy, which shows latency in both eyes now (only left eye before).

Further therapy with Rituximab is planned in India.

Narendra
Jana



Dr. med. S. Klaffke
Fachärztin für Neurologie

Narendra
Jana